BEAM

Beam Therapeutics Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↑ 6/10
  • Value↓ 0/10
Beam Therapeutics sales and earnings growth
BEAM Growth
Good
  • Revenue Y/Y↑ 120.01%
  • EPS Y/Y↑ 82.31%
  • FCF Y/Y↓ -1.08%
Beam Therapeutics gross and profit margin trends
BEAM Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -57.20%
  • ROIC 5Y↓ -26.61%
Beam Therapeutics net debt vs free cash flow
BEAM Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Beam Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗